ArticleClinical and experimental medicine2025
Interferon alpha-induced uPAR expression on monocytes as a potential source of increased soluble uPAR in patients with SLE at high risk of developing organ damage.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The soluble urokinase plasminogen activator receptor (suPAR) has been shown to adequately predict the risk of organ damage development in patients with systemic lupus erythematosus (SLE). However, the cellular source and mechanism of increased circulating levels remain unknown. The cell-bound uPAR is expressed on various cell types and can be shed from the plasma membrane surface by proteases, resulting in the soluble form, suPAR. Herein, leukocyte uPAR expression and plasma suPAR levels were explored in unstimulated and cytokine-treated (tumor necrosis factor; TNF or interferon-α; IFN-α) blood from patients with SLE (n = 37) and healthy blood donors (HBD; n = 27). Unstimulated or cytokine-treated whole blood was thereafter used for analysis of cellular uPAR expression by flow cytometry, and plasma suPAR levels by enzyme-linked immunosorbent assay (ELISA). Monocytes and neutrophils had the most prominent uPAR expression and showed increased expression after TNF addition to the blood (p < 0.001). Addition of IFN-α resulted in increased uPAR expression only in patients (p < 0.05). No differences in uPAR expression were found depending on organ damage or other clinical variables. Nevertheless, suPAR levels were higher in patients with organ damage (p < 0.01). Unstimulated suPAR levels were correlated with monocyte uPAR expression in patient samples (rho = 0.4). As circulating suPAR levels can predict organ damage development in SLE, it is important to unravel its potential disease mediating effects as well as cellular sources. Results of this study suggest IFN-α as a regulator of uPAR expression in SLE and monocyte uPAR as an important source of plasma suPAR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.